Breast Cancer: Targets and Therapy (Nov 2021)
Detection of Minimal Residual Disease in the Peripheral Blood of Breast Cancer Patients, with a Multi Marker (MGB-1, MGB-2, CK-19 and NY-BR-1) Assay
Abstract
Suzy E Meijer,1,2 Olga Klebanov-Akopyn,3 Vera Pavlov,2,3 Shachar Laks,4 David Hazzan,4 Aviram Nissan,2– 4 Douglas Zippel3,4 1Department of Infectious Disease, Sourasky Medical Center, Tel Aviv, Israel; 2The Surgical Oncology Laboratory, Hadassah-Hebrew University Hospital, Jerusalem, Israel; 3The Surgical Oncology Laboratory, The Chaim Sheba Medical Center, Ramat Gan, Israel; 4Department of General and Oncological Surgery – Surgery C, The Chaim Sheba Medical Center, Ramat Gan, IsraelCorrespondence: Douglas ZippelDepartment of General & Oncological Surgery-Surgery C, The Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, IsraelTel +972-3-530-2714Fax +972-3-5341562Email [email protected]: Minimal residual disease (MRD) refers to micrometastases that are undetectable by conventional means and is a potential source of disease relapse. This study aimed to detect the presence of breast cancer (BC) biomarkers (MGB-1, MGB-2, CK-19, NY-BR-1) using real-time polymerase chain reaction (RT-PCR) in peripheral blood mononuclear cells (PBMC) of BC patients and the impact of a positive assay on clinical outcome.Patients and Methods: Patients in the analysis included females > 18 years of age with biopsy-proven carcinoma of the breast. A 10 mL sample of venous blood was obtained from 10 healthy controls and 25 breast cancer patients. Comparisons of peripheral blood markers were made with clinicopathological variables.Results: High-quality RNA was extracted from all samples with a mean RNA concentration of 224.8± 155.3 ng/μL. Each of the molecular markers examined was highly expressed in the primary breast tumors (n = 3, positive controls) with none of the markers detected in healthy negative controls. The NY-BR-1 marker was expressed in one (4%) patient with metastatic disease with no MGB-1 and MGB-2 detected in any sample derived from the study patients. The CK-19 marker was detected in 16 (64%) of the BC cases. No correlation was found between CK-19 expression and tumor stage (P = 0.07) or nodal status (P = 0.32). No correlation was identified in the BC patients between CK-19 expression and receptor status in the BC primary tumor.Conclusion: This study showed high expression of all 4 markers NY-BR-1, MGB-1, MGB-2 and CK-19 in the PBMCs derived from breast cancer patients. CK-19 was detected in 64% of the stage I–III cases operated with curative intent, the only recurrent events occurring in the CK-19-positive cases. Our data confirm the need to enhance techniques for detection of MRD, which may better predict patients at risk for relapse.Keywords: breast cancer, circulating tumor cells, cancer biomarkers, early detection, predictive potential
